^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice

Published date:
11/14/2022
Excerpt:
KRAS mutant NSCLC patients received chemotherapy or immunotherapy as first-line treatment from September 2014 to March 2022 were enrolled….Subgroup analysis revealed the benefits of immunotherapy compared to chemotherapy were applicable in PD-L1 expression≥1% subgroup...
DOI:
https://doi.org/10.1186/s12885-022-10236-9